TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01989858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peri-operative cht
Description: CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative CHT
Description: CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peri-operative cht + post-operative cht-rtx
Description: CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
Study: NCT04152304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sinex program (neuromuscular training program)
Description: The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
Study: NCT01736800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
Study: NCT01989858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative cht + post-operative cht-rtx
Description: CHT treatment have to be chosen between the following associations:~* EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~* ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~* 5FU 225 mg/m² given as a continuous iv infusion or~* capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.
Study: NCT02160626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle
Description: Placebo control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 (40) Topical Solution
Description: A-101 (40) Topical Solution - high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 (32.5) Topical Solution
Description: A-101 (32.5) Topical Solution - low dose
Study: NCT01326871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
Study: NCT01736800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
Study: NCT00171808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT00560560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-751, 871
Description: Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
Study: NCT02869516

Intervention type: OTHER
Intervention: Clinical data collection
Study: NCT01629732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
Study: NCT00805259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: Financial incentives based on use of software designed to promote cognitive function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: Financial incentives based on use of software designed to promote cognitive function
Study: NCT01629732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film coated tablet, Oral, 60 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986094
Description: Capsule, Oral, 200 mg, Once daily, 24 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986094
Description: Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986094
Description: Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
Study: NCT00037830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM1 ganglioside
Description: 100 mg twice per day by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice per day subcutaneous injection, equal volume as active drug
Study: NCT03651622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric, low carbohydrate diet
Description: Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
Study: NCT00805259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentives
Description: Financial incentives based on use of software designed to promote cognitive function
Study: NCT03651622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric, moderate low fat diet
Description: Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet, no caloric restriction
Description: Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
Study: NCT01269723

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprout homogenate
Description: Subjects will drink the broccoli shake homogenate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alfalfa sprout homogenate
Description: Subjects will drink the alfalfa sprout homogenate.
Study: NCT01517295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Dose: Standard prescribed dose Frequency: Once Duration: Once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Description: Dose: Standard prescribed dose Frequency: Once Duration: Once
Study: NCT04559984

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel
Study: NCT03353220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belviq
Description: Belviq is an oral drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belviq
Description: Belviq is an oral drug
Study: NCT00741559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetoencephalography
Description: MEG studies are performed using a whole-head Omega 151-channel gradiometer system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
Study: NCT01786759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: the lipid of all-in-one, 0.5-3.5g/kg.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: the lipid of all-in-one, 0.5-3.5g/kg.d
Study: NCT01432184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: strategies to reverse decrease in rSO2
Description: an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
Study: NCT02840344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples MBSR
Description: Both members of the couple will be asked to participate in the weekly video sessions and activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual MBSR
Description: Only the young breast cancer survivor will participate in the weekly video sessions and activities.
Study: NCT03472248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
Study: NCT00006011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03353220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is made to mimic Belviq, but does not contain any active drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is made to mimic Belviq, but does not contain any active drug
Study: NCT03186755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.05% & Ectoine 2.0%
Description: Treatment of 1 drop three times a day in both eyes for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution 0.1%
Description: Treatment of 1 drop two times a day in both eyes for 8 weeks
Study: NCT00666237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tube shunt surgery
Description: The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Description: The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
Study: NCT01548599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sectoral agricultural intervention
Description: Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
Study: NCT02873689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules
Study: NCT04361656

Intervention type: DRUG
Intervention: PEG-ELS current standard of care
Description: Standard of care for inpatient colonoscopy

Intervention type: DRUG
Intervention: PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
Description: The dose of Lubiprostone will be 24 mcg capsule orally (roughly every 12 hours) for total of 2 doses, with the last dose being at least 4 hours prior to the scheduled colonoscopy if it is BEFORE 11 a.m., and Lubiprostone 24 mcg capsule orally 2 hours before each dose of the PEG-ELS if colonoscopy is scheduled AT or AFTER 11 a.m..
Study: NCT00981617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (1 mg)
Description: 1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (2.5 mg)
Description: 2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Study: NCT00006011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00831753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP IPV HB PRP~T vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-HB-IPV and Haemophilus influenzae type b
Description: 0.5 mL, Intramuscular
Study: NCT02541877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Down sizing valve in type-0 BAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sizing valve in type-0 BAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sizing valve in TAS
Description: Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
Study: NCT01004848

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-Led Lifestyle Education on Weight Loss
Description: Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Lifestyle Education on Weight Loss
Description: Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
Study: NCT00981617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS33 (RDC-0313) (10 mg)
Description: 10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily for 12 weeks
Study: NCT01092468

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Diathermy
Description: flap dissection with conventional diathermy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic Scalpel
Description: flap dissection using harmonic scalpel (FOCUS)
Study: NCT03150043

Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo Rainbow Pulse CO-oximeter
Description: Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery